Extending the curve: survival of EGFR-mutated lung cancer patients in the 21^st century

Lung cancer remains the most lethal malignancy worldwide (1,2). Although incidence rates have decreased in part of the developed world, other regions face the challenge of an epidemic of paramount importance, which is likely to take hundreds of thousands of lives in the coming years (2,3).